Skip to main content

Wenzel Spine announces FDA clearance to launch VariLift®-LX

 

Clinical courses

 

Clinical research courses

Wenzel Spine, Inc., a pioneer medical device company focused on providing minimally invasive, stand-alone alternatives to traditional spinal fusion, announced today that it received clearance from the U.S. Food and Drug Administration (FDA) to market VariLift®-LX as an interbody fusion device for stand-alone use in the lumbar spine.

VariLift®-LX represents the next generation of Wenzel Spine’s innovative product lines of zero-profile, stand-alone, expandable interbody fusion devices.

Like the full line of VariLift® lumbar devices, VariLift®-LX is indicated to be implanted in a unilateral or bilateral capacity via a PLIF or TLIF approach and may be used stand-alone, without supplemental fixation.

<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>